{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:45:38Z","timestamp":1782488738130,"version":"3.54.5"},"reference-count":56,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C23338\/A25722"],"award-info":[{"award-number":["C23338\/A25722"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-NOV21\/100003"],"award-info":[{"award-number":["DRCRPG-NOV21\/100003"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breast Cancer Now","award":["2023.05PR1664"],"award-info":[{"award-number":["2023.05PR1664"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,1,10]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current immunotherapy regimens most often fail due to an insufficient T cell response and\/or immune-related adverse events (irAEs) which lead to treatment discontinuation. Additionally, many cancers likely require combination immunotherapies which may further increase irAE. This is exemplified in our preclinical models of dual targeting of regulatory T cells with a phosphoinositide 3-kinase \u03b4 (PI3K\u03b4) inhibitor and antibodies to LAG-3. Indeed, while this approach in preclinical models of triple-negative breast cancer shows excellent tumor control, treatment is poorly tolerated and results in significant toxicity. Given the emerging relevance of these targets in human breast cancer, we explored strategies to sustain tumor immunity while mitigating toxicity using these therapeutic modalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Different approaches to combination immunotherapies employing a PI3K\u03b4 inhibitor (PI-3065) with LAG-3 targeting treatments were tested in a mouse model of triple-negative breast cancer to optimize tumor control while limiting irAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Systemic targeting of the LAG-3 ligand FGL1 did not provide additional anticancer benefit but markedly worsened irAE. Localized delivery of anti-LAG-3 antibodies to the tumor microenvironment promoted tumor control while reducing the overall number of animals experiencing severe irAE compared with those receiving systemic LAG-3 blockade. However, intermittent dosing of the PI3K\u03b4 inhibitor in combination with anti-LAG-3 treatment prevented the initial development of irAE and enabled excellent tumor control without systemic adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data demonstrated that refining immunotherapy delivery approaches can improve tolerability that ultimately transforms treatment success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012157","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:30:22Z","timestamp":1770049822000},"page":"e012157","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing anti-PI3K\u03b4 and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04328844","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06879717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06717126","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06644183","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03849469","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03219268","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02460224","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04328844","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2561-6277","authenticated-orcid":false,"given":"Sarah Nicol","family":"Lauder","sequence":"first","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pires","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Somerville","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Capitani","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Smart","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Geary","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M","family":"Mills","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Vanhaesebroeck","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Godkin","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-7004","authenticated-orcid":false,"given":"Awen","family":"Gallimore","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026062607450851000_14.2.e012157.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2026062607450851000_14.2.e012157.2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2026062607450851000_14.2.e012157.3","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-PATHOL-042020-042741"},{"key":"2026062607450851000_14.2.e012157.4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1703481","article-title":"Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062607450851000_14.2.e012157.5","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.3390\/curroncol31100473","article-title":"Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors","volume":"31","author":"Cheema","year":"2024","journal-title":"Curr Oncol"},{"key":"2026062607450851000_14.2.e012157.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7"},{"key":"2026062607450851000_14.2.e012157.7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0131"},{"key":"2026062607450851000_14.2.e012157.8","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00262-020-02603-x","article-title":"Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion","volume":"69","author":"Hughes","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2026062607450851000_14.2.e012157.9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imm.13082","article-title":"Phosphoinositide 3-kinase \u03b4 is a regulatory T-cell target in cancer immunotherapy","volume":"157","author":"Lim","year":"2019","journal-title":"Immunology"},{"key":"2026062607450851000_14.2.e012157.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1839"},{"key":"2026062607450851000_14.2.e012157.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701703"},{"key":"2026062607450851000_14.2.e012157.12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature New Biol"},{"key":"2026062607450851000_14.2.e012157.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000693","article-title":"Enhanced antitumor immunity through sequential targeting of PI3K\u03b4 and LAG3","volume":"8","author":"Lauder","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062607450851000_14.2.e012157.14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120626","article-title":"Phosphoinositide 3-kinase \u03b4 inhibition promotes antitumor responses but antagonizes checkpoint inhibitors","volume":"3","author":"Lim","year":"2018","journal-title":"JCI Insight"},{"key":"2026062607450851000_14.2.e012157.15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026062607450851000_14.2.e012157.16","doi-asserted-by":"crossref","first-page":"e1604","DOI":"10.1634\/theoncologist.2020-0321","article-title":"A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"25","author":"Borazanci","year":"2020","journal-title":"Oncologist"},{"key":"2026062607450851000_14.2.e012157.17","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.1200\/JCO.2024.42.16_suppl.9597","article-title":"Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K\u03b4) in patients with uveal melanoma and advanced cancers","volume":"42","author":"Di Giacomo","year":"2024","journal-title":"JCO"},{"key":"2026062607450851000_14.2.e012157.18","doi-asserted-by":"crossref","unstructured":"Amato G , Simonetti E , Graham J , et al . First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3K\u03b4) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results. 2022 ASCO Annual Meeting I: Journal of Clinical Oncology; 2022 doi:10.1200\/JCO.2022.40.16_suppl.3107","DOI":"10.1200\/JCO.2022.40.16_suppl.3107"},{"key":"2026062607450851000_14.2.e012157.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0194"},{"key":"2026062607450851000_14.2.e012157.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246168","article-title":"A novel mouse model for checkpoint inhibitor-induced adverse events","volume":"16","author":"Adam","year":"2021","journal-title":"PLoS One"},{"key":"2026062607450851000_14.2.e012157.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.037"},{"key":"2026062607450851000_14.2.e012157.22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature New Biol"},{"key":"2026062607450851000_14.2.e012157.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2026062607450851000_14.2.e012157.24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2023.06.024","article-title":"Relatlimab-nivolumab: A practical overview for dermatologists","volume":"89","author":"Mullick","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026062607450851000_14.2.e012157.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.010"},{"key":"2026062607450851000_14.2.e012157.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"2026062607450851000_14.2.e012157.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-54041-9","article-title":"Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade","volume":"14","author":"Rivoltini","year":"2024","journal-title":"Sci Rep"},{"key":"2026062607450851000_14.2.e012157.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2026062607450851000_14.2.e012157.29","doi-asserted-by":"publisher","DOI":"10.1177\/0300985813485099"},{"key":"2026062607450851000_14.2.e012157.30","doi-asserted-by":"crossref","DOI":"10.1186\/1746-6148-9-123","article-title":"Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology--a systematic review","volume":"9","author":"Klopfleisch","year":"2013","journal-title":"BMC Vet Res"},{"key":"2026062607450851000_14.2.e012157.31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026062607450851000_14.2.e012157.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2"},{"key":"2026062607450851000_14.2.e012157.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.08.010"},{"key":"2026062607450851000_14.2.e012157.34","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab025","article-title":"Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity","volume":"2","author":"Burnell","year":"2022","journal-title":"Immunother Adv"},{"key":"2026062607450851000_14.2.e012157.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y"},{"key":"2026062607450851000_14.2.e012157.36","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000119"},{"key":"2026062607450851000_14.2.e012157.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.11.014"},{"key":"2026062607450851000_14.2.e012157.38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011401","article-title":"Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Pacha","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026062607450851000_14.2.e012157.39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1556\/EuJMI.1.2011.3.4","article-title":"In vitro induced CD8+ regulatory T cells inhibit skin inflammation","volume":"1","author":"Fleissner","year":"2011","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"2026062607450851000_14.2.e012157.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02221-1"},{"key":"2026062607450851000_14.2.e012157.41","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1470-2045(22)00333-3","article-title":"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial","volume":"23","author":"Pagel","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026062607450851000_14.2.e012157.42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/bloodadvances.2023010648","article-title":"A phase 2 study of the PI3K\u03b4 inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)","volume":"8","author":"Phillips","year":"2024","journal-title":"Blood Adv"},{"key":"2026062607450851000_14.2.e012157.43","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz413.097","article-title":"Preclinical development of a novel, highly selective PI3K\u03b4 inhibitor, IOA-244, for the treatment of solid malignancies","volume":"30","author":"Johnson","year":"2019","journal-title":"Ann Oncol"},{"key":"2026062607450851000_14.2.e012157.44","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026062607450851000_14.2.e012157.45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.6598"},{"key":"2026062607450851000_14.2.e012157.46","doi-asserted-by":"crossref","unstructured":"Lim EL , Qian Y , Sugihara F , et al . Loss of pi3k\u03b4 activity drives autoimmune colitis by impairing extrathymic treg differentiation. bioRxiv [Preprint]. doi:10.1101\/2024.11.21.624633","DOI":"10.1101\/2024.11.21.624633"},{"key":"2026062607450851000_14.2.e012157.47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264400","article-title":"Differential colitis susceptibility of Th1- and Th2-biased mice: A multi-omics approach","volume":"17","author":"Mukhopadhyay","year":"2022","journal-title":"PLoS ONE"},{"key":"2026062607450851000_14.2.e012157.48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2020.04.006","article-title":"Differences in T regulatory cells between mouse strains frequently used in immunological research: Treg cell quantities and subpopulations in NOD, B6 and BALB\/c mice","volume":"223","author":"Godoy","year":"2020","journal-title":"Immunol Lett"},{"key":"2026062607450851000_14.2.e012157.49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40364-024-00601-0","article-title":"FGL1 and FGL2: emerging regulators of liver health and disease","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark Res"},{"key":"2026062607450851000_14.2.e012157.50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173215","article-title":"Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells","volume":"9","author":"Xi","year":"2024","journal-title":"JCI Insight"},{"key":"2026062607450851000_14.2.e012157.51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026062607450851000_14.2.e012157.52","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12144641","article-title":"Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature","volume":"12","author":"Dibos","year":"2023","journal-title":"J Clin Med"},{"key":"2026062607450851000_14.2.e012157.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.767868","article-title":"Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"2026062607450851000_14.2.e012157.54","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16430"},{"key":"2026062607450851000_14.2.e012157.55","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood.2023022724","article-title":"The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling","volume":"143","author":"Sardo","year":"2024","journal-title":"Blood"},{"key":"2026062607450851000_14.2.e012157.56","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50993-8","article-title":"Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment","volume":"15","author":"Abboud","year":"2024","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:45:28Z","timestamp":1782485128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-012157"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012157","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}